Clinical trial
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
NCT03883113 is registered in ClinicalTrials.gov with Barinthus Biotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
- Lead sponsor
- Barinthus Biotherapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 3, 2019
- Completion date
- April 17, 2020
- Enrollment
- 145 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
influenza